Testosterone Blood Test: Total, Free, Timing, and Context

A testosterone blood test may report total, free, or bioavailable testosterone. Those are different analytical quantities, not three grades of the same “hormone score.” The number does not diagnose a condition, prove why a symptom exists, or create a treatment target.

Start with the exact analyte, value, unit, flag, reference interval, laboratory, collection date and time, and measurement or calculation method. Then add the reason for testing, symptoms, age and hormone context, medicines, supplements, acute illness, and any preparation instructions. That source-aware record is safer than comparing the number with an online “normal” or “optimal” range.

What total, free, and bioavailable testosterone report

Testosterone circulates both unbound and attached to proteins, chiefly sex-hormone-binding globulin (SHBG) and albumin. The National Library of Medicine's testosterone test guide uses these practical definitions:

• Total testosterone includes the unbound and protein-bound fractions.
• Free testosterone is the fraction not attached to a protein.
• Bioavailable testosterone conventionally includes free testosterone plus testosterone attached to proteins other than SHBG, mainly albumin.

These labels describe what an assay or calculation reports. They do not directly measure androgen-receptor signaling, conversion within tissues, symptom cause, fertility, or the effect of testosterone in a particular organ.

Testosterone may be reviewed with related but distinct evidence. For example, estradiol and DHEA-S are not substitute testosterone tests, and a result from one cannot confirm or cancel a result from another.

Why “bound is inactive and free is usable” is too simple

Albumin binds testosterone less tightly than SHBG, which is why free plus albumin-bound testosterone is often labeled bioavailable. But that name is a model and laboratory convention, not proof that one fraction alone determines biological effects.

A multi-society global consensus statement for women says evidence is lacking for treating free testosterone as the uniquely biologically active fraction. A detailed review of testosterone binding likewise describes uncertainty in the traditional free-hormone model and in the equations used to estimate free concentrations.

That does not make free testosterone useless. In selected clinical settings, SHBG can make total testosterone a less complete summary. It means “free is the usable hormone” is not an adequate interpretation—and that the method and reason for ordering free testosterone matter.

A fraction name is not a diagnosis: preserve how the number was produced and which clinical question it was meant to answer.

Measured and calculated free testosterone are not interchangeable

Free testosterone may be separated and measured using equilibrium dialysis, or estimated with a formula using total testosterone, SHBG, and sometimes albumin. The 2018 Endocrine Society male-hypogonadism guideline recommends equilibrium dialysis or an accurate calculation when free testosterone is indicated. It advises against direct analog free-testosterone immunoassays because they are inaccurate.

Equilibrium dialysis is a reference method, but that is not the same as perfect cross-laboratory standardization. Dialysis conditions and downstream measurement can differ. A calculated value inherits error from its input tests and assumptions from its equation. Different valid-looking methods can therefore produce values and reference intervals that should not be mixed silently.

A 2023 joint laboratory and endocrinology position statement also calls equilibrium dialysis followed by mass spectrometry the reference method while warning that other direct methods tend to be inaccurate. Its recommendations concern biochemical confirmation of adult male hypogonadism; they do not make free testosterone the default test for everyone.

Why there is no portable normal or optimal number

Reference intervals depend on the analyte, population, collection protocol, method, and unit. One widely repeated interval illustrates the boundary. A harmonization study used a selected group of 1,185 healthy, nonobese European and American men ages 19 to 39 and CDC-standardized total-testosterone measurements. Its 2.5th and 97.5th percentiles were 264 and 916 ng/dL.

The study authors also found that assay differences explained substantial variation between cohorts. The interval describes that selected population and calibrated methods. It is not a universal range for women, children, older adults, people with obesity or illness, people taking hormones, or results produced by another method. It is not an “optimal” zone or treatment goal for anyone.

The measurement problem is especially important at lower concentrations. The global consensus statement says direct total- and free-testosterone assays are highly unreliable in the female range, and it states that no circulating androgen cutoff distinguishes women with and without sexual dysfunction.

Use the interval on the source report as one population comparison, then ask whether it fits the clinical question. The guide to laboratory reference ranges explains why an in-range value does not prove health and a flag does not establish disease.

What a low or high result can—and cannot—show

Testosterone testing can contribute to several different evaluations: symptoms of possible deficiency in adult men, signs of androgen excess, puberty timing, fertility questions, prior abnormal results, and hormone-therapy monitoring are examples. These purposes use different populations, related tests, and clinical criteria.

For men being evaluated for hypogonadism, the Endocrine Society requires relevant symptoms or signs plus unequivocally and consistently low accurately measured testosterone concentrations. Its July 2026 statement also recommends against population screening of asymptomatic men. Low energy, libido changes, mood changes, and other commonly marketed symptoms have many possible explanations and do not diagnose hypogonadism by themselves.

That male-hypogonadism definition does not become a universal rule for women, young people, people with possible androgen excess, or people using hormone therapy. In every population, one concentration alone cannot identify a cause, establish urgency, or decide whether treatment is needed.

When morning, fasting, illness, and repeat testing matter

For men being evaluated for hypogonadism, current Endocrine Society guidance calls for at least two early-morning fasting testosterone tests. Testosterone varies within and between days, and acute illness can temporarily alter the evaluation. The 2018 guideline reports that 30% of men whose first value was in the hypogonadal range had a normal concentration on repeat measurement.

Those facts explain why one low value is not enough for that diagnosis. They do not instruct every person with every testosterone test to fast, repeat a draw, or use the same collection schedule. A test for androgen excess, puberty, or hormone-therapy monitoring may have a different protocol. Follow the complete order's instructions, because co-ordered tests may add preparation requirements.

Do not stop a medicine or hormone to prepare for testing unless the prescribing clinician gives that instruction. Record the collection time, fasting status if known, acute illness, sleep or shift-work context when relevant, and whether the draw followed the supplied directions.

Medicines and hormone therapy change the question

Testosterone, estrogen, glucocorticoids, opioids, some anticonvulsants, some hormone contraceptives, supplements, and other products may alter production, binding proteins, measurement, or the reason a result is being monitored. A plausible influence is not proof that a particular product caused an individual result.

When testosterone is measured during hormone therapy, preserve the product, route, dose as prescribed, schedule, and collection timing relative to the most recent dose if known. The clinician compares the result with the therapy's purpose and monitoring plan. Endocrine Society gender-incongruence guideline resources illustrate that hormone concentrations during gender-affirming care belong to a defined treatment and safety-monitoring context—not to the untreated-male hypogonadism rule or a generic internet range.

Do not start, stop, delay, or change testosterone, estrogen, contraception, glucocorticoids, opioids, supplements, or any other medicine because of this article or one result. Make the complete list available to the ordering and prescribing clinicians.

A trend needs comparable evidence

A sequence is not automatically a trend. Before describing a rise or fall, compare total versus free versus bioavailable testosterone, measured versus calculated status, units, laboratories, methods, intervals, collection time, fasting status, illness, and hormone-dose timing. CDC's current HoSt certification process improves analytical comparability for certified procedures, but it does not make different analytes, populations, or clinical questions interchangeable.

The workflow for combining results from different labs shows how to keep an unresolved comparison visible. Even when two values are comparable, the line documents numerical change; it does not prove symptom improvement, worsening health, a cause, or a treatment effect.

A five-step way to prepare a testosterone result

1. Preserve the result identity

Keep total, free, or bioavailable testosterone; measured or calculated status; value, unit, flag, source interval, laboratory, specimen, collection date and time, and method together. Save the original report when possible.

2. Define the clinical question

Record why the test was ordered and the applicable age, sex, reproductive, puberty, symptom, and hormone-therapy context. Do not import a cutoff from a different population or purpose.

3. Record collection and therapy context

Preserve the supplied preparation instructions, collection time, fasting status if known, acute illness, medicines, supplements, hormone products, route, schedule, and timing relative to a dose. Record facts without assigning a cause.

4. Check method and comparability

Before describing a trend, compare the analyte, unit, laboratory, interval, assay or calculation, collection conditions, and therapy context. Keep results separate when a meaningful difference is unresolved.

5. Prepare bounded questions

Useful questions for the ordering clinician include:

• What exact analyte and method produced this result?
• Does the report interval apply to this clinical question and hormone context?
• If free testosterone was reported, was it measured or calculated, and which inputs or equation were used?
• Do the collection time, preparation, illness, medicines, supplements, or hormone-dose timing affect how this result should be reviewed?
• Is another measurement appropriate for this specific purpose, and under what conditions?
• Which symptoms, signs, or changes should alter the follow-up plan?

A source-aware record note

A bounded summary can read: “Exact testosterone analyte, measured or calculated status, value, unit, report interval, laboratory, method, date and time, preparation, illness context, medicines, supplements, hormone regimen, reason for testing, and symptoms preserved; comparability and cause not assumed.”

That sentence does not decide whether the value is low or high for the person, name a condition, recommend repeat testing, or change a treatment. It keeps the evidence needed for those decisions from being stripped away.

Where Libby fits

Libby can support the organization layer: keeping the source report, result identity, value, unit, interval, method, collection details, related records, medicine and hormone context, and questions together. It does not reconcile assays or equations, determine which range applies, diagnose a hormone condition, assess urgency, order testing, or recommend a medicine or dose.

The complete guide to reading blood-test results keeps organization, interpretation, and treatment in separate lanes. If that record workflow would help, you can start your record.

FAQ

What is the difference between total, free, and bioavailable testosterone? Total includes free and protein-bound testosterone. Free is unbound. Bioavailable conventionally combines free and non-SHBG-bound testosterone, mainly the albumin-bound fraction. Each label identifies a different analytical quantity; none directly measures tissue action.

Does bound testosterone mean inactive and free testosterone mean usable? No. That shortcut overstates a contested physiological model. Albumin binding is reversible, and evidence does not establish free testosterone as the only biologically active fraction. Preserve the method and interpret the result in its clinical context.

Is 264 to 916 ng/dL a normal testosterone range for everyone? No. Those were the 2.5th and 97.5th percentiles in 1,185 healthy, nonobese European and American men ages 19 to 39 using CDC-standardized total-testosterone measurements. The interval is not portable to another population, method, or personal target.

Does one low testosterone result diagnose low T or hypogonadism? No. For men evaluated for hypogonadism, current guidance requires relevant symptoms or signs plus consistently low accurately measured concentrations. Other populations and clinical questions use different criteria.

Why are early-morning fasting and repeat tests discussed? They are part of the current diagnostic protocol for men evaluated for hypogonadism because concentrations vary and illness or collection conditions can affect the result. They are not universal instructions for every testosterone test.

Can I compare testosterone results from different laboratories? Only after checking the analyte, unit, method, calculation, interval, collection conditions, and clinical context. Standardization can improve analytical agreement, but different free-testosterone methods and equations may still produce non-interchangeable values.

What should I record if I take hormones or medicines? Keep the complete product and medicine list, prescribed dose and route, schedule, and collection timing relative to a hormone dose if known. Do not change a medicine for testing unless the prescribing clinician tells you to.

References

• Testosterone Levels Test — MedlinePlus
• Statement on Testosterone Replacement Therapy — Endocrine Society, 2026
• Testosterone Therapy in Men With Hypogonadism — Endocrine Society Clinical Practice Guideline
• Improving Performance: Hormone Standardization Program — CDC
• Standardising the Biochemical Confirmation of Adult Male Hypogonadism — PubMed Central
• Harmonized Reference Ranges for Circulating Testosterone Levels in Men — PubMed Central
• Global Consensus Position Statement on the Use of Testosterone Therapy for Women — PubMed Central
• Reappraisal of Testosterone's Binding in Circulation — PubMed Central
• Gender Dysphoria and Gender Incongruence Guideline Resources — Endocrine Society